Our Trials

ADP-A2M10 Triple Tumor Clinical Trial

This is a Phase I, open label, dose escalation clinical trial designed to evaluate the safety and anti-tumor activity of Adaptimmune's ADP- A2M10 (MAGE-A10) therapeutic candidate in patients who are HLA-A*02 positive and have inoperable locally advanced or metastatic melanoma, urothelial or head and neck cancers that express MAGE- A10. The primary objective of the clinical trial is to evaluate the safety and tolerability of ADP- A2M10 SPEAR T- cell therapy. Further details are available via the link below.

View Clinical Trial

Publications

Please visit our Publications page for more information on ADP-A2M10 (MAGE-A10)

Triple Tumor Clinical Trial

To learn more about triple tumor visit the Cancer Information page or click the link below.